We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+3.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.45B
AUM Growth
-$54.5M
Cap. Flow
+$154M
Cap. Flow %
10.62%
Top 10 Hldgs %
43.38%
Holding
129
New
42
Increased
32
Reduced
24
Closed
24
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.6 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.6 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
LH icon
Labcorp
LH
+$37.6M
2
CYH icon
Community Health Systems
CYH
+$28.3M
3
ASND icon
Ascendis Pharma A/S
ASND
+$27.8M
4
CTLT icon
CATALENT, INC.
CTLT
+$23M
5
MASI icon
Masimo
MASI
+$18.2M

Top Sells

Rank Stock Value
1
QGEN icon
Qiagen
QGEN
+$26.7M
2
AMRN icon
Amarin Corp
AMRN
+$24.9M
3
OGN icon
Organon & Co
OGN
+$21.2M
4
DHR icon
Danaher
DHR
+$17.4M
5
AMN icon
AMN Healthcare
AMN
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 80.74%
2 Miscellaneous 17.65%
3 Industrials 1.16%
4 Financials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
UTHR icon
1
United Therapeutics
UTHR
$22.8B
$82M 5.67%
444,471
+1,526
+0.3% +$301K
2020 Q2
5 quarters
ASND icon
2
Ascendis Pharma A/S
ASND
$14.8B
$71M 4.91%
445,203
+203,429
+84% +$27.8M
2017 Q4
15 quarters
CYH icon
3
Community Health Systems
CYH
$410M
$70.1M 4.85%
5,988,163
+2,166,434
+57% +$28.3M
2020 Q4
3 quarters
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$69.5M 4.81%
634,670
-32,068
-5% -$3.33M
2020 Q2
5 quarters
XLRN
5
DELISTED
Acceleron Pharma
XLRN
$60.1M 4.16%
349,494
+14,449
+4% +$1.89M
2021 Q1
2 quarters
AMRN icon
6
Amarin Corp
AMRN
$238M
$59.2M 4.09%
580,250
-253,224
-30% -$24.9M
2018 Q1
14 quarters
GSK icon
7
CALL
GSK
GSK
$99.4B
$57.5M 3.97%
1,202,960
+80,000
+7% +$4.02M
2020 Q4
3 quarters
AZN icon
8
AstraZeneca
AZN
$255B
$53.5M 3.7%
445,404
-47,457
-10% -$5.52M
2019 Q4
7 quarters
AVTR icon
9
Avantor
AVTR
$10.9B
$52.8M 3.65%
1,292,014
+317,377
+33% +$12.4M
2020 Q4
3 quarters
ARKG icon
10
ARK Genomic Revolution ETF
ARKG
$1.99B
$51.5M 3.56%
689,501
-83,979
-11% -$7.05M
2021 Q1
2 quarters
DHR icon
11
Danaher
DHR
$161B
$45.1M 3.12%
166,874
-64,033
-28% -$17.4M
2018 Q3
12 quarters
SPY icon
12
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$805B
$42.9M 2.97%
100,000
-150,000
-60% -$66.2M
2021 Q1
2 quarters
AMRX icon
13
Amneal Pharmaceuticals
AMRX
$6.64B
$36.6M 2.53%
6,849,834
+1,225,109
+22% +$6.17M
2020 Q2
5 quarters
LH icon
14
Labcorp
LH
$25.8B
$36.1M 2.5%
+149,354
New +$37.6M
2021 Q3
0 quarters
TEVA icon
15
Teva Pharmaceutical Industries Limited
TEVA
$48.1B
$34.6M 2.39%
3,554,804
-249,601
-7% -$2.34M
2020 Q3
4 quarters
NVST icon
16
Envista
NVST
$3.7B
$33.9M 2.34%
810,881
+154,783
+24% +$6.53M
2020 Q4
3 quarters
MCK icon
17
McKesson
MCK
$117B
$32.3M 2.23%
161,708
+86,708
+116% +$17.3M
2021 Q1
2 quarters
VRTX icon
18
CALL
Vertex Pharmaceuticals
VRTX
$127B
$31.4M 2.17%
173,300
– –
2021 Q1
2 quarters
BMY icon
19
Bristol-Myers Squibb
BMY
$124B
$27.8M 1.92%
464,801
-13,527
-3% -$891K
2021 Q2
1 quarter
CTLT icon
20
DELISTED
CATALENT, INC.
CTLT
$24.5M 1.7%
+184,299
New +$23M
2021 Q3
0 quarters
ICLR icon
21
Icon
ICLR
$13.1B
$18.8M 1.3%
+71,911
New +$17.5M
2021 Q3
0 quarters
MASI icon
22
DELISTED
Masimo
MASI
$18.1M 1.25%
+67,000
New +$18.2M
2021 Q3
0 quarters
OCDX
23
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
$16.9M 1.17%
914,986
-479,298
-34% -$9.65M
2021 Q1
2 quarters
RCM icon
24
DELISTED
R1 RCM Inc. Common Stock
RCM
$16.8M 1.16%
764,780
-5,220
-0.7% -$108K
2021 Q2
1 quarter
MRVI icon
25
Maravai LifeSciences
MRVI
$1.02B
$16.1M 1.11%
327,810
+252,810
+337% +$12.3M
2021 Q2
1 quarter
1
2 3 4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q3 2021 Portfolio in Review

As of Q3 2021, Eversept Partners held 129 positions worth $1.45B, down 3.6% from $1.5B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Eversept Partners deployed $154M of net new capital in Q3 2021, opening 42 new positions and adding to 32 existing holdings. Its largest new stake was Labcorp: 149,354 shares worth $36.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 65% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Qiagen, an estimated $26.7M trimmed.

  • Eversept Partners's largest Q3 2021 buy was Labcorp: 149,354 shares worth $36.1M.
  • Eversept Partners added most to Community Health Systems in Q3 2021, an estimated $28.3M increase.
  • Eversept Partners's biggest Q3 2021 reduction was Qiagen, cutting an estimated $26.7M.
  • Eversept Partners fully exited Organon & Co in Q3 2021, selling an estimated $21.2M.
  • Eversept Partners's ten largest holdings make up 43% of its $1.45B portfolio in Q3 2021.
  • Eversept Partners opened 42 new positions and closed 24 in Q3 2021.
  • Eversept Partners's portfolio value fell 3.6% quarter-over-quarter to $1.45B.

Based on Eversept Partners's 13F filing for Q3 2021, filed 15 Nov 2021.